+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Aerie Pharmaceuticals - logo

Aerie Pharmaceuticals is a company that focuses on the development and commercialization of therapies for the treatment of glaucoma and other eye diseases. The National Eye Institute expects the number of people in the United States suffering from glaucoma to reach 4.3 million by 2030. Aerie was founded in 2005 and went in public in 2013, raising $67 million in its IPO. Its product candidates include Rhopressa and Roclatan. The company is headquartered in Irvine, California.

From
From
From
From
From
From
From
Glaucoma Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Glaucoma Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • February 2024
  • 360 Pages
  • Global
From
From
From
Glaucoma Therapeutics Market Report and Forecast 2023-2031 - Product Thumbnail Image

Glaucoma Therapeutics Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 160 Pages
  • Global
From
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020 - Product Thumbnail Image

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 57 Pages
  • Global
From
Corneal Endothelial Dystrophy - Pipeline Insight, 2024 - Product Thumbnail Image

Corneal Endothelial Dystrophy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Loading Indicator